HYLS1: A Novel Biomarker for Aging and Disease (G219844)

Target Name: HYLS1

NCBI ID: G219844

HYLS1

HYLS1: A Novel Biomarker for Aging and Disease

HYLS1 (Human Years Life Score) is a novel biomarker that has been identified as a potential drug target in the field of aging and age-related diseases. HYLS1 is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and bones. It is a key regulator of cellular processes that are associated with aging, such as the formation of beta-crosslinked networks in tissues, which are thought to contribute to the aging process.

One of the key features of HYLS1 is its ability to interact with a variety of transcription factors, including nuclear factor kappa B (NFkB), which is a well-known regulator of inflammation and stress responses. NFkB is a protein that is expressed in many different tissues throughout the body, and it is involved in a wide range of cellular processes, including inflammation, DNA damage repair, and cell survival.

HYLS1 has been shown to play a role in the regulation of NFkB activity, and it is thought to be a potential drug target for diseases that are characterized by inflammation or aging. For example, studies have shown that HYLS1 is expressed in tissues that are affected by a variety of age-related conditions, including Alzheimer's disease, Parkinson's disease, and cardiovascular disease. Additionally, HYLS1 has been shown to be involved in the regulation of cellular responses to stress, such as stress-induced inflammation.

Another key feature of HYLS1 is its ability to interact with the protein p53, which is a well-known regulator of DNA damage repair. p53 is a protein that is expressed in many different tissues throughout the body, and it is involved in a wide range of cellular processes, including DNA damage repair, apoptosis, and cell survival. HYLS1 has been shown to play a role in the regulation of p53 activity, and it is thought to be a potential drug target for diseases that are characterized by DNA damage or dysfunction.

In conclusion, HYLS1 is a novel biomarker that has been identified as a potential drug target for diseases that are characterized by inflammation or aging. Its ability to interact with transcription factors NFkB and p53, as well as its role in the regulation of cellular processes that are associated with aging, make it an attractive target for drug development. Further research is needed to fully understand the mechanisms of HYLS1's role in the aging process and its potential as a drug target.

Protein Name: HYLS1 Centriolar And Ciliogenesis Associated

Functions: Plays a role in ciliogenesis

The "HYLS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HYLS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets